A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

This study is to evaluates the safety and tolerability of Zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with End-Stage Renal Disease.

Study Overview

• Status: Completed
• Conditions: Hyperphosphatemia; End-stage Renal Disease
• Intervention / Treatment: Drug: ferric citrate

Detailed Description

The purpose of this study is to evaluate the safety and tolerability of Zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with End-Stage Renal Disease. These patients will be switched to Zerenex™ from their current high dose of phosphate binder and, based on their serum phosphorus levels, will be titrated up from 3.4g/day of Zerenex™ to maximum tolerated and safe doses of Zerenex™. Doses will be adjusted weekly, based on serum phosphorus levels, with the maximum dose administered being approximately 12g/day.

• Study Type: Interventional
• Enrollment (Actual): 55
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Tennessee
    • Nashville, Tennessee, United States, 37232
      • Vanderbilt University Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males and non-pregnant, nonlactating females
• Age > 18 years
• On thrice weekly hemodialysis for at least the previous 3 months prior to randomization
• Phosphorous levels ≥3.5mg/dL at Screening Visit
• On at least 12 tablets/capsules/day of calcium acetate (667mg), calcium carbonate (500mg), lanthanum carbonate (500mg), sevelamer hydrochloride (800mg or two 400mg tablets), or any combination of these agents
• Serum ferritin <1000micrograms/L and Transferrin Saturation (TSAT) <50%
• Willing to be discontinued from current phosphate binder(s) and initiated on Zerenex
• Willing and able to give informed consent

Exclusion Criteria:

• Parathyroidectomy within 6 months prior to Screening
• Actively symptomatic GI disease such as peptic ulcer disease, gastro esophageal reflux, diverticulosis, irritable bowel syndrome (treated asymptomatic is permitted)
• History of documented inflammatory bowel disease or erosive esophagitis
• Serum Phosphorus levels >10.0 mg/dL documented in the 3 monthly laboratories (done routinely in the dialysis unit) in the 3 months prior to the Screening Visit
• History of multiple drug allergies
• History of malignancy in the last 5 years (treated cervical or skin cancer may be permitted if approved by CCC)
• Previous intolerance to oral ferric citrate
• Absolute requirement for oral iron therapy
• Absolute requirement for Vitamin C (multivitamins [Neprocaps, Renaphro, etc.] allowed)
• Absolute requirement for calcium, magnesium, or aluminum containing drugs with meals
• Psychiatric disorder that interferes with the patient's ability to comply with the study protocol
• Inability to tolerate oral drug intake
• Planned surgery or hospitalization during the study (scheduled outpatient access surgery allowed)
• Any other medical condition that renders the patient unable to or unlikely to complete the study or that would interfere with optimal participation in the study or produce significant risk to the patient
• Receipt of any investigational drug within 30 days of randomization
• Inability to cooperate with study personnel or history of noncompliance

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: KRX-0502 (ferric citrate); All patients will be switched from their current phosphate binder to Zerenex, and titrated to the maximum tolerated dose (up to about 12g/day) based on their serum phosphorus levels.	Drug: ferric citrate; ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.; Other Names: KRX-0502

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The Difference in Serum Phosphorus Between Baseline (Day 0) and End of Treatment (Day 28)	28 days

Collaborators and Investigators

• Sponsor: Keryx Biopharmaceuticals
• Collaborators: Collaborative Study Group (CSG)
• Investigators: Study Chair: Julia B Lewis, MD, Collaborative Study Group at the Nephrology Clinical Trials Center, Vanderbilt University Medical Center

Publications and helpful links

Helpful Links

• Sponsor

Study record dates

Study Major Dates

• Study Start: March 1, 2008
• Primary Completion (Actual): January 1, 2009
• Study Completion (Actual): January 1, 2009

Study Registration Dates

• First Submitted: March 27, 2008
• First Submitted That Met QC Criteria: March 31, 2008
• First Posted (Estimate): April 1, 2008

Study Record Updates

• Last Update Posted (Actual): April 4, 2017
• Last Update Submitted That Met QC Criteria: March 3, 2017
• Last Verified: March 1, 2017

More Information

Terms related to this study

• Keywords: renal; dialysis; ESRD; end-stage renal disease; renal failure; kidney; hemodialysis; phosphorus; kidney failure; end stage renal disease; phosphate binder
• Additional Relevant MeSH Terms: Metabolic Diseases; Urologic Diseases; Renal Insufficiency; Renal Insufficiency, Chronic; Phosphorus Metabolism Disorders; Kidney Diseases; Kidney Failure, Chronic; Hyperphosphatemia
• Other Study ID Numbers: KRX-0502-201

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO